Habib and colleagues show that type 1 IFN signaling is triggered by EGFR inhibition in nonsmall cell lung cancer models and propose EGFR inhibition and IFN-neutralizing antibody as a potential combination therapy approach.
- Ke Gong
- Gao Guo
- Amyn A. Habib